Clinical Trial Search

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0

Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04

Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period — NA; NA weeks

Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year

Primary: Rate of Change in Brain Parenchymal Fraction — 0.107; -0.355 percentage of change in brain volume — p=0.346

Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale

Primary: Number of Participants With Treatment-emergent Adverse Events — 18 Participants

Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…

Primary: Kinematics — 15.5; 10 degrees

Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change

Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51

Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442

Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 93.8; 91.3; 94.4; 91.2 percentage of participants

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: Rate of Development of Clinical Definite Multiple Sclerosis (CDMS) Over 10 Years — 58; 69 Percent cumulative probability — p=0.001

Primary: Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration — 6; 16 Participants — p=0.521

Primary: Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine. — 12; 6 adverse events

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Annualized Relapse Rate (ARR) — 0.02 relapses per year

Primary: Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II — 56.1; 53.6 units on a scale — p=0.926

Primary: Modified Fatigue Impact Scale — 46.1; 46.7 units on a scale — p=.64

Primary: Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) — 11.97; 12.04 months — p=0.0026

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. — 5.66; 6.60 score on a scale — p=0.51

Primary: MRI Parameter- Percent Brain Volume Change for 2 Years — -0.862; -0.49 percent change per year